Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 23 | 5162 | 32.9 | 82% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 116 | 23742 | STAPHYLOCOCCUS AUREUS//MRSA//METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | PANTON VALENTINE LEUKOCIDIN | Author keyword | 241 | 77% | 3% | 164 |
| 2 | MRSA | Author keyword | 226 | 26% | 14% | 742 |
| 3 | CA MRSA | Author keyword | 203 | 82% | 2% | 117 |
| 4 | METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | Author keyword | 203 | 33% | 10% | 515 |
| 5 | STAPHYLOCOCCUS AUREUS | Author keyword | 98 | 11% | 17% | 875 |
| 6 | METHICILLIN RESISTANCE | Author keyword | 71 | 34% | 3% | 172 |
| 7 | SCCMEC | Author keyword | 68 | 58% | 2% | 78 |
| 8 | PVL | Author keyword | 64 | 61% | 1% | 68 |
| 9 | NASAL CARRIAGE | Author keyword | 58 | 53% | 1% | 77 |
| 10 | USA300 | Author keyword | 53 | 78% | 1% | 35 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | PANTON VALENTINE LEUKOCIDIN | 241 | 77% | 3% | 164 | Search PANTON+VALENTINE+LEUKOCIDIN | Search PANTON+VALENTINE+LEUKOCIDIN |
| 2 | MRSA | 226 | 26% | 14% | 742 | Search MRSA | Search MRSA |
| 3 | CA MRSA | 203 | 82% | 2% | 117 | Search CA+MRSA | Search CA+MRSA |
| 4 | METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS | 203 | 33% | 10% | 515 | Search METHICILLIN+RESISTANT+STAPHYLOCOCCUS+AUREUS | Search METHICILLIN+RESISTANT+STAPHYLOCOCCUS+AUREUS |
| 5 | STAPHYLOCOCCUS AUREUS | 98 | 11% | 17% | 875 | Search STAPHYLOCOCCUS+AUREUS | Search STAPHYLOCOCCUS+AUREUS |
| 6 | METHICILLIN RESISTANCE | 71 | 34% | 3% | 172 | Search METHICILLIN+RESISTANCE | Search METHICILLIN+RESISTANCE |
| 7 | SCCMEC | 68 | 58% | 2% | 78 | Search SCCMEC | Search SCCMEC |
| 8 | PVL | 64 | 61% | 1% | 68 | Search PVL | Search PVL |
| 9 | NASAL CARRIAGE | 58 | 53% | 1% | 77 | Search NASAL+CARRIAGE | Search NASAL+CARRIAGE |
| 10 | USA300 | 53 | 78% | 1% | 35 | Search USA300 | Search USA300 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MRSA | 587 | 48% | 17% | 885 |
| 2 | PANTON VALENTINE LEUKOCIDIN | 555 | 56% | 13% | 667 |
| 3 | NASAL CARRIAGE | 265 | 44% | 9% | 451 |
| 4 | CASSETTE CHROMOSOME MEC | 217 | 60% | 5% | 235 |
| 5 | METHICILLIN RESISTANT | 173 | 23% | 13% | 655 |
| 6 | SKIN INFECTIONS | 145 | 55% | 3% | 180 |
| 7 | PANDEMIC CLONES | 140 | 92% | 1% | 56 |
| 8 | USA300 | 125 | 72% | 2% | 97 |
| 9 | LEUCOCIDIN GENES | 121 | 97% | 1% | 34 |
| 10 | VALENTINE LEUKOCIDIN GENES | 109 | 70% | 2% | 90 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Waves of resistance: Staphylococcus aureus in the antibiotic era | 2009 | 502 | 146 | 69% |
| Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic | 2010 | 424 | 788 | 70% |
| Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods | 2012 | 91 | 73 | 77% |
| Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) | 2012 | 60 | 49 | 94% |
| Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe | 2010 | 147 | 113 | 93% |
| Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology | 2009 | 153 | 30 | 87% |
| Management of Skin Abscesses in the Era of Methicillin-Resistant Staphylococcus aureus | 2014 | 13 | 37 | 70% |
| The evolution of Staphylococcus aureus | 2008 | 203 | 222 | 91% |
| USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus | 2012 | 41 | 83 | 95% |
| Basis of Virulence in Community-Associated Methicillin-Resistant Staphylococcus aureus | 2010 | 146 | 112 | 68% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ST HYLOCOCCUS REFERENCE UNIT | 35 | 86% | 0.3% | 18 |
| 2 | REFERENCE ST HYLOCOQUES | 30 | 45% | 1.0% | 51 |
| 3 | MRSA REFERENCE | 26 | 69% | 0.4% | 22 |
| 4 | GRAM POSIT BACTERIA TYPING UNIT | 17 | 72% | 0.3% | 13 |
| 5 | MRSA KNOWLEDGE | 14 | 100% | 0.1% | 7 |
| 6 | REFERENCE ST HYLOCOCCI | 11 | 37% | 0.5% | 24 |
| 7 | INFECT DIS CONTROL INT MED | 11 | 29% | 0.6% | 31 |
| 8 | AUSTRALIAN ABORATING ENTEROCOCCUS ST H | 9 | 55% | 0.2% | 11 |
| 9 | REFERENCE MRSA ST HYLOCOQUES | 7 | 38% | 0.3% | 15 |
| 10 | INFECT CONTROL PROGRAM | 7 | 16% | 0.8% | 40 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000198450 | SECTOR MICROBIOL//STAPHYLOCOCCUS AUREUS BACTEREMIA//STAPHYLOCOCCUS AUREUS BACTERAEMIA |
| 2 | 0.0000175496 | TETRACYCLINE RESISTANCE PLASMID//BACTERIOPHAGE TYPING//PI9789 |
| 3 | 0.0000174141 | AMOEBA BACTERIA INTERACTION//ANTIBIOTIC TREATMENTS//BINOMIAL OBSERVATION |
| 4 | 0.0000150462 | MECA GENE//MECA//METHICILLIN RESISTANCE |
| 5 | 0.0000144222 | STAPHYLOCOCCUS PSEUDINTERMEDIUS//STAPHYLOCOCCUS INTERMEDIUS//ST398 |
| 6 | 0.0000119020 | MUPIROCIN RESISTANCE//FUSIDIC ACID//MUPIROCIN |
| 7 | 0.0000107963 | CHLORHEXIDINE BATHING//HEALTHCARE SAFETY NETWORK//CHLORHEXIDINE BODY WASHING |
| 8 | 0.0000101855 | ANTI INFECTIOUS ACTIVITY//DICHLOROMETHYLENE DIPHOSPHATE//FLAP INJURY |
| 9 | 0.0000097786 | DAPTOMYCIN//TELAVANCIN//HVISA |
| 10 | 0.0000082099 | MOYNE PREVENT MED//AGR//HUMAN BACTERIAL PATHOGENESIS |